[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Wolfe F., Clauw D.J., Fitzcharles M.A., Goldenberg D.L., Huser W., Katz R.L., Mease P.J., Russell A.S., Russell I.J., Walitt B
Coschigano, K
You just need clear guidance on cagrilintide and semaglutide used together
Adori C, Daraio T, Kuiper R, et al
If successful in clinical trials and approved, danuglipron could be in a prime position to differentiate based on profile, including full receptor agonism, which we believe has the potential to translate to robust efficacy. However, the company has also announced it will discontinue the clinical development of another GLP-1-RA candidate, lotiglipron, after pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements showed elevated transaminases in these Phase 1 studies as well as the ongoing Phase 2 study